First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

10.1177/1758835919836374

Saved in:
Bibliographic Details
Main Authors: Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Review
Language:English
Published: SAGE PUBLICATIONS LTD 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
afatinib
brain metastases
EGFR tyrosine kinase inhibitors
NSCLC
real-world
uncommon mutations
OPEN-LABEL
BRAIN METASTASES
NAIVE PATIENTS
ACQUIRED-RESISTANCE
PLUS NSCLC
PHASE-III
GEFITINIB
ADENOCARCINOMA
ERLOTINIB
CHEMOTHERAPY
Online Access:https://scholarbank.nus.edu.sg/handle/10635/218616
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/218616

Similar Items